Dioxizol (dioxydine, lidocaine hydrochloride) 50 g. vial

Description

Dioxizol 50 g. Composition
active ingredients: dioxydine, lidocaine hydrochloride;

1 g of solution contains: dioxidine 12 mg, lidocaine hydrochloride 60 mg;

Dioxizol 50 g. excipients: propylene glycol, poloxamer, purified water.

Dioxizol 50 g. Dosage form
Solution.

Basic physical and chemical properties: transparent viscous liquid of light yellow color with a weak specific odor.

Pharmacotherapeutic group
Antibacterial agents. ATX code J01X X.

Pharmacodynamics
Dioxizol®-Darnitsa is a combined drug for topical use, the active ingredients of which are dioxidine and lidocaine. The solution has a strong local anesthetic and moderate hyperosmolar effect, relieves wound and perifocal inflammation, stimulates the reparation processes and the activity of phagocytes in the wound.

Dioxidine has a pronounced antibacterial effect against gram-negative and gram-positive, aerobic and anaerobic, spore-forming and asporogenic microflora (Pseudomonas aeruginosa, staphylococci, streptococci, clostridia, bacteroids, peptococci, etc.) in the form of monocultures and microbial bacteria associations other antibacterial drugs. Its antibacterial action is based on the ability to damage the DNA of bacteria. As a result of this effect, the synthesis of bacterial nucleases is slowed down, the ultrastructure of the bacterial cell is disrupted, the cell membrane thickens and the structure of membranes is disrupted. The cytostatic effect of the drug is due to the effect on the regions of the genome responsible for the synthesis of exoenzymes that cause virulence, which is associated with the ability of the drug to prevent the development of resistance in microorganisms.

Lidocaine has a local anesthetic effect due to the blockade of voltage-dependent Na + -channels, which prevents the generation of impulses at the endings of sensory nerves and the conduction of impulses along nerve fibers. When applied topically, it dilates blood vessels, does not have a local irritating effect. The effect develops within 1–5 minutes after application to the skin.

Pharmacokinetics
Dioxidine, when applied topically, is practically not absorbed and does not have a local irritating effect. It is not metabolized in the body, does not accumulate. It is excreted by the kidneys.

The rate of absorption of lidocaine and the amount of active substance that enters the bloodstream depend on the dose, type, size and condition of the surface to which it is applied (skin or mucous membrane), as well as the duration of exposure.

Lidocaine is well absorbed when applied to the mucous membrane and damaged skin, and poorly when applied to healthy skin. The time to reach the maximum concentration in blood plasma is up to 1 hour. 40-80% of lidocaine binds to blood plasma proteins. Penetrates through the blood-brain and placental barriers, into breast milk. Metabolized in the liver. The half-life of lidocaine is 1.6 hours. It is excreted by the kidneys and with bile: 90–95% – in the form of metabolites, up to 10% – unchanged.

Indications
Infected wounds of soft tissues of various localization and genesis (amputation stumps of the extremities, wounds after surgical treatment of purulent foci, bedsores, trophic ulcers, purulent postoperative wounds and fistulas, paraproctitis, abscesses and phlegmon of the maxillofacial region, etc.);
burns of II – IV degrees;
acute and chronic osteomyelitis;
preparation of wounds for autodermoplasty;
prevention of purulent-inflammatory processes in surgery and combustiology when performing various plastic surgeries.

Contraindications
Hypersensitivity to active substances or to other components of the drug;
arterial hypotension, bradycardia, atrioventricular block II – III degree, cardiogenic shock, hypovolemia;
insufficiency of the adrenal cortex (including a history);
pregnancy and breastfeeding;
childhood.